Literature DB >> 9252358

Preparation and characterization of recombinant tissue inhibitor of metalloproteinase 4 (TIMP-4).

Y E Liu1, M Wang, J Greene, J Su, S Ullrich, H Li, S Sheng, P Alexander, Q A Sang, Y E Shi.   

Abstract

TIMP-4, a novel human tissue inhibitor of metalloproteinase, was identified and cloned (Greene, J., Wang, M., Raymond, L. A., Liu, Y. E., Rosen, C., and Shi, Y. E. (1996) J. Biol. Chem. 271, 30375-30380). In this report, the production and characterization of recombinant TIMP-4 (rTIMP4p) are described. rTIMP4p, expressed in baculovirus-infected insect cells, was purified to homogeneity by a combination of cation exchange, hydrophobic, and size-exclusion chromatographies. The purified protein migrated as a single 23-kDa band in SDS-polyacrylamide gel electrophoresis and in Western blot using a specific anti-TIMP-4 antibody. Inhibition of matrix metalloproteinase (MMP) activities by rTIMP4p was demonstrated in five MMPs. Enzymatic kinetic studies revealed IC50 values (concentration at 50% inhibition) of 19, 3, 45, 8, and 83 nM for MMP-1, MMP-2, MMP-3, MMP-7, and MMP-9, respectively. Purified rTIMP4p demonstrated a strong inhibitory effect on the invasion of human breast cancer cells across reconstituted basement membranes. Thus, TIMP-4 is a new enzymatic inhibitor in MMP-mediated extracellular matrix degradation and may have therapeutic potential in treating cancer malignant progression.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9252358     DOI: 10.1074/jbc.272.33.20479

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  26 in total

1.  Identification, regulation and role of tissue inhibitor of metalloproteinases-4 (TIMP-4) in human platelets.

Authors:  Anna Radomski; Paul Jurasz; Esmond J Sanders; Christopher M Overall; Heather F Bigg; Dylan R Edwards; Marek W Radomski
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

Review 2.  Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease.

Authors:  Joseph D Raffetto; Raouf A Khalil
Journal:  Biochem Pharmacol       Date:  2007-07-07       Impact factor: 5.858

3.  Matrix metalloproteinase therapy in heart failure.

Authors:  Francis G Spinale; Nikole M Wilbur
Journal:  Curr Treat Options Cardiovasc Med       Date:  2009-08

Review 4.  Tissue inhibitor of metalloproteinases (TIMPs) in heart failure.

Authors:  Linn Moore; Dong Fan; Ratnadeep Basu; Vijay Kandalam; Zamaneh Kassiri
Journal:  Heart Fail Rev       Date:  2012-09       Impact factor: 4.214

5.  Tissue inhibitor of metalloproteinase-2 regulates matrix metalloproteinase-2-mediated endothelial barrier dysfunction and breast cancer cell transmigration through lung microvascular endothelial cells.

Authors:  Qiang Shen; Eugene S Lee; Robert L Pitts; Mack H Wu; Sarah Y Yuan
Journal:  Mol Cancer Res       Date:  2010-06-22       Impact factor: 5.852

Review 6.  Targeting matrix metalloproteinases in heart disease: lessons from endogenous inhibitors.

Authors:  Francis G Spinale; Francisco Villarreal
Journal:  Biochem Pharmacol       Date:  2014-04-26       Impact factor: 5.858

7.  Enhanced cell surface expression of matrix metalloproteinases and their inhibitors, and tumor-induced host response in progression of human gastric carcinoma.

Authors:  Shohei Koyama
Journal:  Dig Dis Sci       Date:  2004-10       Impact factor: 3.199

8.  Effects of age on plasma matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs).

Authors:  D Dirk Bonnema; Carson S Webb; Weems R Pennington; Robert E Stroud; Amy E Leonardi; Leslie L Clark; Catherine D McClure; Laura Finklea; Francis G Spinale; Michael R Zile
Journal:  J Card Fail       Date:  2007-09       Impact factor: 5.712

9.  Cloning and expression of an inhibitor of microbial metalloproteinases from insects contributing to innate immunity.

Authors:  Anja Clermont; Marianne Wedde; Volkhard Seitz; Lars Podsiadlowski; Dido Lenze; Michael Hummel; Andreas Vilcinskas
Journal:  Biochem J       Date:  2004-08-15       Impact factor: 3.857

Review 10.  MMP induction and inhibition in myocardial infarction.

Authors:  Merry L Lindsey
Journal:  Heart Fail Rev       Date:  2004-01       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.